RxDoctor Payments DataLook up a doctor →

Duarte Machado, MD

Neurology · Cheshire, CTNPI 1649454976

Payments from drug & device makers

$439,688in general payments, 2019–2025

Across 1,094 payments — averaging $401.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$109K
  • Adamas Pharmaceuticals, Inc.$72K
  • Amneal Pharmaceuticals LLC$44K
  • AbbVie$44K
  • MDD US Operations, LLC$43K
  • Kyowa Kirin, Inc.$33K
  • plus $94K from 33 others
$7,149in research payments, 2019–2025

Across 3 payments — averaging $2383.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Neurocrine Biosciences, Inc.$6K
  • Medtronic$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$439,688 in reported general payments places this provider in the 90th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$530,050
Medicare patients
327
Services billed
65,950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Cheshire

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →